NEW YORK – After successfully completing its Seagen acquisition late last year, Pfizer has ambitious plans for its oncology ...

NEW YORK – Denovo Biopharma said on Tuesday that California's Institute for Regenerative Medicine (CIRM) has awarded a $11.8 million grant to Denovo and its partners to develop the investigational ...

NEW YORK – Merck said Wednesday that its Phase III KEYNOTE-811 trial met its primary endpoint by showing that the addition of its checkpoint inhibitor Keytruda (pembrolizumab) to Genentech's anti-HER2 ...

NEW YORK – Repare Therapeutics and Debiopharm on Tuesday said they dosed the first patient with the PKMYT1 inhibitor lunresertib and the WEE1 kinase inhibitor Debio 0123 in a new arm of Repare's ...

The firm's gene-editing therapy PM359 is designed to correct a specific variant in the NCF1 gene, which can cause the rare ...

The company's stock dropped more than 60 percent on the release of the Phase II/III data on buntanetap, which included a missed primary endpoint.

The Phase II portion of the Phase I/II trial is evaluating INB-400 and maintenance chemotherapy in newly diagnosed glioblastoma patients.

NEW YORK – Alzheon has dosed the first patient in a long-term extension study of its ongoing pivotal Phase III trial of valiltramiprosate, an oral medication it's developing for patients with a ...

Pfizer also announced a warranty program for payors with potential refunds tied to durability of patients' responses to the ...

In a Phase III trial, the Truqap-Faslodex combo reduced the risk of disease progression or death by 50 percent compared to Faslodex alone.

Kalydeco, already approved for patients as young as 1 month old in the US and UK, is now available to babies that young throughout the Europe Union.

The firm is aiming to give 20 patients SNK01 and 10 patients a placebo in this Phase I/IIa trial slated to begin dosing in the second half of this year.